BioAtla, Inc. (BCAB)
NASDAQ: BCAB · Real-Time Price · USD
0.168
-0.000 (-0.06%)
At close: Mar 6, 2026, 4:00 PM EST
0.174
+0.006 (3.52%)
After-hours: Mar 6, 2026, 7:41 PM EST
BioAtla Revenue
In the year 2024, BioAtla had annual revenue of $11.00M.
Revenue (ttm)
$11.00M
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
61
Market Cap
12.46M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BioLineRx | 12.74M |
| Traws Pharma | 2.85M |
| CytoMed Therapeutics | 573.19K |
| BioCardia | 3.00K |
| Soligenix | 2.34K |
BCAB News
- 5 days ago - BioAtla Announces Formal Process to Evaluate Strategic Options to Monetize Assets - GlobeNewsWire
- 2 months ago - BioAtla and GATC Health Announce a $40 Million Special Purpose Vehicle (SPV) Transaction to Advance Ozuriftamab Vedotin (Oz-V) into a Registrational Trial for 2L+ Oropharyngeal Squamous Cell Carcinoma (OPSCC) - GlobeNewsWire
- 3 months ago - BioAtla Enters into Agreements for up to $22.5 Million Flexible Financing - GlobeNewsWire
- 4 months ago - BioAtla, Inc. (BCAB) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 4 months ago - BioAtla Reports Third Quarter 2025 Financial Results and Highlights Recent Progress - GlobeNewsWire
- 4 months ago - BioAtla's Mecbotamab Vedotin (Mec-V), an AXL-targeting ADC, Demonstrates a Median Overall Survival (OS) of 21.5 months in Subtypes of Refractory Soft Tissue Sarcomas - GlobeNewsWire
- 4 months ago - BioAtla to Announce Third Quarter 2025 Financial Results and Provide Business Highlights on November 13, 2025 - GlobeNewsWire
- 4 months ago - BioAtla Presents Compelling Mechanistic Rationale for Targeting ROR2 with Ozuriftamab Vedotin (Oz-V) in Oropharyngeal Squamous Cell Carcinoma (OPSCC) at the Annual Conference of the International Papillomavirus Society - GlobeNewsWire